FR-008-III

Category

FR-008-III




Useful info

FR-008-III Brand names, FR-008-III Analogs

FR-008-III Brand Names Mixture

  • No information avaliable

    • FR-008-III Chemical_Formula

    C12H17NO2

    FR-008-III RX_link

    http://www.rxlist.com/cgi/generic3/penlac.htm

    FR-008-III fda sheet

    FR-008-III FDA

    FR-008-III msds (material safety sheet)

    FR-008-III MSDS

    FR-008-III Synthesis Reference

    No information avaliable

    FR-008-III Molecular Weight

    207.269 g/mol

    FR-008-III Melting Point

    144 oC

    FR-008-III H2O Solubility

    No information avaliable

    FR-008-III State

    Solid

    FR-008-III LogP

    2.33

    FR-008-III Dosage Forms

    Topical solution (8%)

    FR-008-III Indication

    Used as a topical treatment in immunocompetent patients with mild to moderate onychomycosis of fingernails and toenails without lunula involvement, due to Trichophyton rubrum.

    FR-008-III Pharmacology

    Ciclopirox is a broad-spectrum antifungal medication that also has antibacterial and anti-inflammatory properties. Its main mode of action is thought to be its high affinity for trivalent cations, which inhibit essential co-factors in enzymes. Ciclopirox exhibits either fungistatic or fungicidal activity in vitro against a broad spectrum of fungal organisms, such as dermatophytes, yeasts, dimorphic fungi, eumycetes, and actinomycetes. In addition to its broad spectrum of action, ciclopirox also exerts antibacterial activity against many Gram-positive and Gram-negative bacteria. Furthermore, the anti-inflammatory effects of ciclopirox have been demonstrated in human polymorphonuclear cells, where ciclopirox has inhibited the synthesis of prostaglandin and leukotriene. Ciclopirox can also exhibit its anti-inflammatory effects by inhibiting the formation of 5-lipoxygenase and cyclooxygenase.

    FR-008-III Absorption

    Rapidly absorbed after oral administration. Mean absorption of ciclopirox after application to nails of all twenty digits and adjacent 5 millimeters of skin once daily for 6 months in patients with dermatophytic onychomycoses was less than 5% of the applied dose. Ciclopirox olamine also penetrates into hair and through the epidermis and hair follicles into sebaceous glands and dermis.

    FR-008-III Toxicity

    Oral LD50 in rat is >10 ml/kg. Symptoms of overexposure include drowsiness and headache.

    FR-008-III Patient Information

    No information avaliable

    FR-008-III Organisms Affected

    Humans, other mammals, yeast and other fungi